Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT02786485 Withdrawn - Multiple Myeloma Clinical Trials

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Start date: May 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, open-label, non-randomized study of matched unrelated donor BPX-501 T cell infusion in adult subjects with hematological malignancies presenting with recurrent disease minimal residual disease (MRD) post-allogeneic transplant.

NCT ID: NCT02784418 Withdrawn - Clinical trials for Coronary Artery Disease

The SHINE-CTO Trial

SHINE-CTO
Start date: May 2016
Phase: N/A
Study type: Interventional

Design: Single center, double-blind, sham-controlled trial that will randomize symptomatic patients with a coronary chronic total occlusion (CTO) to CTO percutaneous coronary intervention (PCI) or a sham procedure. All patients will receive optimal medical therapy. Treatment:CTO PCI, as per standard clinical practice. Control: Patients randomized to sham-procedure will undergo only bilateral arterial access, without angiography or PCI being performed. Secondary Endpoints: (1) Greater improvement in SAQ-7 Summary scores during the entire duration of follow-up (6 months) using a repeated measures analysis (2) Greater improvement in individual components of patients' health status (3) Greater improvement in exercise capacity (4) Similar incidence of major adverse cardiac events (MACE), both peri-procedural and long-term

NCT ID: NCT02784067 Withdrawn - Clinical trials for Genetic Sucrase-Isomaltase Deficiency

A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency

GSID-E
Start date: May 2016
Phase: Phase 4
Study type: Interventional

S09A is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel study examining the efficacy and safety of a Sucraid (sacrosidase) Oral Solution in comparison to a placebo in 150-200 subjects with chronic diarrhea possibly attributable to sucrase deficiency.

NCT ID: NCT02780830 Withdrawn - Clinical trials for Module 1: Non-GCB Diffuse Large B-Cell Lymphoma

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

INHIBITOR
Start date: June 2016
Phase: Phase 1
Study type: Interventional

This is a modular study of AZD2014 in combination with novel anti-cancer agents in patients with different subtypes of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). Module 1, a combination with ibrutinib in patients with non-germinal centre B-cell-like (non-GCB) DLBCL, will consist of Part A, a Phase I dose-finding arm in which the safety and tolerability of the combination will be assessed, and Part B, a Phase II dose-expansion phase to assess the efficacy of the combination.

NCT ID: NCT02779257 Withdrawn - Clinical trials for Gastro-enteropancreatic Neuroendocrine Tumor

Pasireotide Treatment for Neuroendocrine Tumor

Start date: April 2016
Phase: Phase 4
Study type: Interventional

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.

NCT ID: NCT02779153 Withdrawn - Clinical trials for Systemic Lupus Erythematosus (SLE)

Acthar SLE (Systemic Lupus Erythematosus)

Acthar SLE
Start date: October 2016
Phase: Phase 4
Study type: Interventional

This is a randomized study exploring the efficacy, safety and steroid sparing ability of two doses (40 U and 80 U) of Acthar in SLE patients with immune mediated hematologic manifestations requiring steroid use for a minimum of 2 weeks prior to screening.

NCT ID: NCT02775188 Withdrawn - Clinical trials for Anterior Cruciate Ligament Reconstruction

interACTION: A Portable Joint Function Monitoring and Training System to Supplement Home Exercise Programs Following Anterior Cruciate Ligament Reconstruction

Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to ascertain if home-based therapy with monitoring via telemedicine can overcome many barriers to compliance and improve rehabilitation following ACL reconstruction. Patients undergoing ACL Reconstruction will be followed for 6 weeks during their outpatient physical therapy treatment. Subjects will undergo weekly physical therapy or weekly physical therapy paired with InterACTION.

NCT ID: NCT02768012 Withdrawn - Clinical trials for Other Substance Induced Sexual Dysfunction

Mindfulness for Antidepressant-induced Sexual Symptoms

MASS
Start date: July 2016
Phase: N/A
Study type: Interventional

Antidepressant-induced sexual dysfunction (AISD) affects the majority of women taking antidepressants and reduces medication compliance: however there is a paucity of evidence-based strategies for the management of this condition. Mindfulness-based cognitive therapy (MBCT) has been shown to be effective in the treatment of non-antidepressant-induced sexual dysfunction and may be beneficial in the treatment of AISD. The investigators propose a randomized, controlled, proof-of-principle trial to establish preliminary evidence of efficacy of MBCT in AISD and to inform the design of a larger trial to evaluate its effectiveness

NCT ID: NCT02765841 Withdrawn - Clinical trials for Homozygous Familial Hypercholesterolemia

Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy

Start date: May 2016
Phase: Phase 3
Study type: Interventional

This is a Phase 3 single-arm, open-label, international, multi-center clinical trial to evaluate the efficacy and safety of lomitapide in pediatric patients with HoFH who are receiving stable lipid-lowering therapy, including LDL apheresis. The study is comprised of a 12-week Run-in Period, a primary 24-week Efficacy Phase, followed by an 80-week Safety Phase.

NCT ID: NCT02756130 Withdrawn - Clinical trials for Recurrent Ovarian Carcinoma

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: August 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.